Kalvista Pharmaceuticals Inc (NASDAQ:KALV) CFO Benjamin L. Palleiko sold 3,073 shares of the company’s stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $25.70, for a total value of $78,976.10. Following the completion of the sale, the chief financial officer now owns 33,573 shares of the company’s stock, valued at $862,826.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

KALV opened at $25.97 on Wednesday. The company has a market capitalization of $447.91 million, a price-to-earnings ratio of -16.97 and a beta of 2.49. Kalvista Pharmaceuticals Inc has a 1-year low of $7.73 and a 1-year high of $34.92.

Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.22. The company had revenue of $3.89 million for the quarter, compared to analysts’ expectations of $3.97 million. Kalvista Pharmaceuticals had a negative return on equity of 19.12% and a negative net margin of 70.08%. Equities analysts predict that Kalvista Pharmaceuticals Inc will post -1.43 EPS for the current fiscal year.

A number of equities research analysts have weighed in on KALV shares. BidaskClub downgraded Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th. Zacks Investment Research downgraded Kalvista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 21st. Needham & Company LLC started coverage on Kalvista Pharmaceuticals in a research report on Wednesday, March 20th. They issued a “buy” rating and a $35.00 target price for the company. Finally, ValuEngine upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $28.60.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Flinton Capital Management LLC bought a new position in shares of Kalvista Pharmaceuticals in the fourth quarter valued at $26,000. Ramsey Quantitative Systems bought a new position in shares of Kalvista Pharmaceuticals in the fourth quarter valued at $35,000. Bank of Montreal Can bought a new position in shares of Kalvista Pharmaceuticals in the fourth quarter valued at $90,000. Dimensional Fund Advisors LP bought a new position in shares of Kalvista Pharmaceuticals in the third quarter valued at $274,000. Finally, BlackRock Inc. increased its holdings in shares of Kalvista Pharmaceuticals by 19.2% in the third quarter. BlackRock Inc. now owns 19,309 shares of the specialty pharmaceutical company’s stock valued at $427,000 after buying an additional 3,104 shares in the last quarter. 77.37% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.watchlistnews.com/insider-selling-kalvista-pharmaceuticals-inc-kalv-cfo-sells-3073-shares-of-stock/2983571.html.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Further Reading: Net Asset Value

Insider Buying and Selling by Quarter for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.